TMP-SMX Dosing for Moderate Wound Infection
For a resident without renal impairment with a moderate wound infection, the appropriate dosage is 1-2 double-strength tablets (160/800 mg) twice daily for 7-10 days 1, 2, 3.
Specific Dosing Recommendations
Standard Adult Dosing
- 1-2 double-strength (DS) tablets twice daily is the established regimen for skin and soft tissue infections (SSTIs) 1, 2
- Each DS tablet contains trimethoprim 160 mg and sulfamethoxazole 800 mg
- The FDA-approved dosing for various infections supports this twice-daily regimen 3
Duration of Therapy
- 7-10 days is appropriate for moderate wound infections 1, 2
- Duration depends on clinical response and severity of infection
- For uncomplicated SSTIs, 7 days is typically sufficient 2
Clinical Context and Evidence
The 2014 IDSA guidelines for skin and soft tissue infections specifically list TMP-SMX as an option for both MSSA and MRSA infections 2. The dosing of 1-2 DS tablets twice daily is consistently recommended across multiple clinical scenarios:
- For MSSA infections: TMP-SMX is listed as an alternative oral agent with bactericidal activity 1, 2
- For MRSA infections: The same dosing applies, though efficacy data are more limited compared to other agents 1, 2
Important Considerations
Efficacy concerns: The guidelines note that TMP-SMX efficacy is "poorly documented" for SSTIs 1, 2. Recent high-quality research provides more reassurance:
- A 2016 randomized trial showed TMP-SMX (320/1600 mg twice daily for 7 days) achieved 92.9% cure rates for drained abscesses in MRSA-prevalent settings 4
- Another 2016 trial comparing TMP-SMX to clindamycin found similar cure rates (91.9% vs 92.1%) for uncomplicated wound infections 5
Resistance patterns: Recent data from 2025 highlight emerging TMP-SMX resistance in S. aureus isolated from diabetic foot ulcers, emphasizing the importance of culture-guided therapy when possible 6.
Practical Algorithm
- Start empirically with 1-2 DS tablets twice daily if MRSA is suspected or prevalent in your area
- Obtain wound cultures before initiating therapy when feasible
- Adjust based on susceptibility results at 48-72 hours
- Monitor clinical response at 48-72 hours; if no improvement, consider alternative agents
- Complete 7-10 days of therapy based on clinical improvement
Pitfalls to Avoid
- Do not use in sulfa-allergic patients - consider clindamycin or doxycycline instead 1, 2
- Ensure adequate hydration to prevent crystalluria 7
- Avoid in pregnancy (Category C) and nursing mothers due to kernicterus risk 7
- Check for drug interactions, particularly with warfarin, methotrexate, and oral hypoglycemics 7
When TMP-SMX May Not Be Optimal
Consider alternative agents if:
- Local S. aureus resistance to TMP-SMX exceeds 10-20%
- Patient has documented sulfa allergy
- Infection involves streptococcal species (TMP-SMX has poor streptococcal coverage) 1, 2
- Patient is pregnant or breastfeeding 7
The combination therapy of TMP-SMX plus rifampin has shown promise in recent in vitro studies for MRSA, including resistant strains, though this is not yet standard practice 8.